At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 82 enrolled
Drug / intervention
Temsirolimus (CCI-779) +1 moredrug
Likely dose
Temsirolimus (CCI-779) 20 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2, Non Randomized, Open Label Study Of Temsirolimus (CCI-779) In Subjects With Advanced Renal Cell Carcinoma (RCC)
In Brief
A Phase 2 clinical trial evaluating Temsirolimus (CCI-779) for Advanced Renal Cell Carcinoma. Completed, enrolled 82 participants across 24 sites in 3 countries.
Detailed Summary
This is a study to evaluate the safety, efficacy and pharmacokinetics of temsirolimus in Asian patients with advanced renal cell carcinoma. The trial is only being conducted in Japan, Korea, and China.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Renal Cell Carcinoma
CountriesChina, Japan, South Korea
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
First PostedJun 2007
Primary CompletionMay 2011
Study CompletionMar 2012
TodayJul 2026
First PostedJun 29, 2007
Enrollment StartFeb 1, 2007
Primary CompletionMay 1, 2011
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 19.0 years ago
Interventions
Temsirolimus (CCI-779)drug
20 mg/m2 IV TEMSR weekly (Japan, n=6)
Temsirolimus (CCI-779)drug
25 mg IV TEMSR weekly (all other pts)